| Preoperative chemoradiotherapy for esophageal or junctional cancer P van Hagen, M Hulshof, JJB Van Lanschot, EW Steyerberg, ... New England Journal of Medicine 366 (22), 2074-2084, 2012 | 5702 | 2012 |
| Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial J Shapiro, JJB Van Lanschot, MCCM Hulshof, P van Hagen, ... The lancet oncology 16 (9), 1090-1098, 2015 | 2523 | 2015 |
| Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in … RR Bahadoer, EA Dijkstra, B van Etten, CAM Marijnen, H Putter, ... The Lancet Oncology 22 (1), 29-42, 2021 | 1227 | 2021 |
| Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor YH Kusumanto, WA Dam, GAP Hospers, C Meijer, NH Mulder Angiogenesis 6, 283-287, 2003 | 650 | 2003 |
| Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab B Weide, A Martens, JC Hassel, C Berking, MA Postow, K Bisschop, ... Clinical Cancer Research 22 (22), 5487-5496, 2016 | 592 | 2016 |
| Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research D Bouïs, GAP Hospers, C Meijer, G Molema, NH Mulder Angiogenesis 4, 91-102, 2001 | 546 | 2001 |
| Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial BM Eyck, JJB van Lanschot, MCCM Hulshof, BJ van der Wilk, J Shapiro, ... Journal of Clinical Oncology 39 (18), 1995-2004, 2021 | 491 | 2021 |
| Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind … YH Kusumanto, V Van Weel, NH Mulder, AJ Smit, J Van Den Dungen, ... Human gene therapy 17 (6), 683-691, 2006 | 441 | 2006 |
| In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft WB Nagengast, EG De Vries, GA Hospers, NH Mulder, JR De Jong, ... Journal of Nuclear Medicine 48 (8), 1313-1319, 2007 | 436 | 2007 |
| Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma S Kelderman, B Heemskerk, H Van Tinteren, RRH Van Den Brom, ... Cancer Immunology, Immunotherapy 63, 449-458, 2014 | 377 | 2014 |
| Rectal and colon cancer: Not just a different anatomic site K Tamas, AME Walenkamp, EGE De Vries, M Van Vugt, RG Beets-Tan, ... Cancer treatment reviews 41 (8), 671-679, 2015 | 367 | 2015 |
| Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer–the RAPIDO trial PJ Nilsson, B van Etten, GAP Hospers, L Påhlman, CJH van de Velde, ... BMC cancer 13, 1-9, 2013 | 355 | 2013 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The Lancet Oncology 22 (5), 643-654, 2021 | 341 | 2021 |
| Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study J Larkin, M Del Vecchio, PA Ascierto, I Krajsova, J Schachter, B Neyns, ... The lancet oncology 15 (4), 436-444, 2014 | 327 | 2014 |
| Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma MW Rohaan, TH Borch, JH Van Den Berg, Ö Met, R Kessels, ... New England journal of medicine 387 (23), 2113-2125, 2022 | 276 | 2022 |
| Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma KA Lee, AM Thomas, LA Bolte, JR Björk, LK de Ruijter, F Armanini, ... Nature Medicine 28 (3), 535-544, 2022 | 269 | 2022 |
| PET imaging of oestrogen receptors in patients with breast cancer M van Kruchten, EGE de Vries, M Brown, EFJ de Vries, ... The Lancet Oncology 14 (11), e465-e475, 2013 | 242 | 2013 |
| A review on pro-and anti-angiogenic factors as targets of clinical intervention D Bouïs, Y Kusumanto, C Meijer, NH Mulder, GAP Hospers Pharmacological Research 53 (2), 89-103, 2006 | 239 | 2006 |
| Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer M van Kruchten, EG de Vries, AW Glaudemans, MC van Lanschot, ... Cancer discovery 5 (1), 72-81, 2015 | 218* | 2015 |
| Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial ILM Reijers, AM Menzies, ACJ Van Akkooi, JM Versluis, ... Nature medicine 28 (6), 1178-1188, 2022 | 212 | 2022 |
